A Randomized, Two-Treatments, Two-Periods, Crossover, Open label, Laboratory-Blind, Single Dose Bioequivalence Study between Vildagliptin/Metformin 50 mg/1000 mg Film Coated Tablets (Sensityn®) and Galvusmet® 50 mg/1000 mg Film Coated Tablets in healthy adults under fed conditions

A Randomized, Two-Treatments, Two-Periods, Crossover, Open label, Laboratory-Blind, Single Dose Bioequivalence Study between Vildagliptin/Metformin 50 mg/1000 mg Film Coated Tablets (Sensityn®) and Galvusmet® 50 mg/1000 mg Film Coated Tablets in healthy adults under fed conditions

Vildagliptin/metformin 50 mg/1000 mg film coated tablets (Sensityn®) is being developed for the treatment of type 2 diabetes mellitus. An open label, crossover, bioequivalence study (phase I) was conducted to assess the bioequivalence between Sensityn® Film Coated Tablets (Test Product/Alpha Pharma...

Full description

Bibliographic Details
Main Authors: Shiekmydeen J., Siddiqi T., Chakraborty K., Khalaf S., Albarazi M., Eqtefan I., Sliva J.
Format: Article
Language:English
Published: Sciendo 2023-10-01
Series:European Pharmaceutical Journal
Subjects:
bioequivalence
diabetes mellitus
metformin
pharmacokinetics
vildagliptin
Online Access:https://doi.org/10.2478/afpuc-2023-0019

Internet

https://doi.org/10.2478/afpuc-2023-0019

Similar Items